- Home
- RARE vs AX Comparison
RARE vs AX Comparison
Compare RARE & AX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RARE
- AX
- Stock Information
- Founded
- RARE 2010
- AX 1999
- Country
- RARE United States
- AX United States
- Employees
- RARE N/A
- AX N/A
- Industry
- RARE Biotechnology: Pharmaceutical Preparations
- AX Savings Institutions
- Sector
- RARE Health Care
- AX Finance
- Exchange
- RARE Nasdaq
- AX Nasdaq
- Market Cap
- RARE 3.6B
- AX 3.7B
- IPO Year
- RARE 2014
- AX 2005
- Fundamental
- Price
- RARE $33.84
- AX $64.44
- Analyst Decision
- RARE Strong Buy
- AX Buy
- Analyst Count
- RARE 15
- AX 6
- Target Price
- RARE $95.93
- AX $84.17
- AVG Volume (30 Days)
- RARE 748.6K
- AX 428.6K
- Earning Date
- RARE 05-01-2025
- AX 04-29-2025
- Dividend Yield
- RARE N/A
- AX N/A
- EPS Growth
- RARE N/A
- AX 10.06
- EPS
- RARE N/A
- AX 7.40
- Revenue
- RARE $560,230,000.00
- AX $1,175,999,000.00
- Revenue This Year
- RARE $19.15
- AX $21.13
- Revenue Next Year
- RARE $32.11
- AX $5.53
- P/E Ratio
- RARE N/A
- AX $8.72
- Revenue Growth
- RARE 29.01
- AX 25.02
- 52 Week Low
- RARE $33.69
- AX $44.10
- 52 Week High
- RARE $60.37
- AX $88.46
- Technical
- Relative Strength Index (RSI)
- RARE 27.75
- AX 46.28
- Support Level
- RARE $36.71
- AX $62.20
- Resistance Level
- RARE $39.21
- AX $64.92
- Average True Range (ATR)
- RARE 1.34
- AX 1.68
- MACD
- RARE -0.32
- AX 0.28
- Stochastic Oscillator
- RARE 2.19
- AX 50.89
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About AX Axos Financial Inc.
Axos Financial Inc is a bank holding company that operates through its bank subsidiary, BofI Federal Bank, a nationwide bank that provides financing for single and multifamily residential properties, small to medium-size businesses in certain sectors, and selected specialty finance receivables. Its operating segments are banking business segment and securities business segment . The bank distributed its products through a wide range of retail distribution channels, including only banking brands, affinity groups, and sales teams, among others. The majority of the bank's mortgage exposure is titled toward the state of California, particularly its southern region. Net interest income is a majority of the bank's revenue.